Once dominated by Western markets, China and India are now emerging as leaders in small molecule development. Indeed, they ...

The European Commission has approved Swiss pharma giant Roche’s Itovebi (inavolisib), in combination with palbociclib ...

Privately-held Spanish CNS specialist Minoryx Therapeutics and Germany’s Neuraxpharm Group today announce that the marketing authorization application (MAA) for Minoryx’ lead candidate Nezglyal ...

After 13 years at the helm of the UK’s BioIndustry Association, Steve Bates has tendered his resignation as chief executive ...

Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide.

Patients in the UK will now be able to access advanced, personalized treatments prepared at the hospital or even in mobile ...

Swiss pharma Sandoz (SIX: SDZ) has spent less than a year charting its course as an independent company, but already it’s ...

Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to ...

Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ ...

Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million ...

Shares of French clinical-stage biotech Abivax were up an astonishing 389% at 43.55 euros in early trading, after, late yesterday, it announced positive top-line results from its Phase III ABTECT-1 ...

French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: Mari Scheiffele is appointed executive vice president (EVP) , chief product officer, Andreas ...